BR112017003552A2 - ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? - Google Patents

?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?

Info

Publication number
BR112017003552A2
BR112017003552A2 BR112017003552A BR112017003552A BR112017003552A2 BR 112017003552 A2 BR112017003552 A2 BR 112017003552A2 BR 112017003552 A BR112017003552 A BR 112017003552A BR 112017003552 A BR112017003552 A BR 112017003552A BR 112017003552 A2 BR112017003552 A2 BR 112017003552A2
Authority
BR
Brazil
Prior art keywords
treat
increase
methods
body mass
life
Prior art date
Application number
BR112017003552A
Other languages
English (en)
Portuguese (pt)
Inventor
Duus Elizabeth
Baroni Enrico
Friend John
Lu Ming
Giorgino Ruben
Allen Suzan
Mann William
Polvino William
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017003552(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of BR112017003552A2 publication Critical patent/BR112017003552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112017003552A 2014-09-04 2015-08-28 ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? BR112017003552A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
BR112017003552A2 true BR112017003552A2 (pt) 2017-12-05

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003552A BR112017003552A2 (pt) 2014-09-04 2015-08-28 ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?

Country Status (44)

Country Link
US (5) US9675600B2 (enExample)
EP (2) EP3188599B1 (enExample)
JP (3) JP6356907B2 (enExample)
KR (3) KR102234319B1 (enExample)
CN (5) CN107375285A (enExample)
AP (1) AP2017009772A0 (enExample)
AR (1) AR103118A1 (enExample)
AU (1) AU2015312231B2 (enExample)
BR (1) BR112017003552A2 (enExample)
CA (1) CA2959158A1 (enExample)
CL (1) CL2017000494A1 (enExample)
CO (1) CO2017003263A2 (enExample)
CR (1) CR20170121A (enExample)
CY (1) CY1122746T1 (enExample)
DK (1) DK3188599T3 (enExample)
DO (1) DOP2017000055A (enExample)
EA (1) EA035578B1 (enExample)
EC (1) ECSP17019893A (enExample)
ES (1) ES2761777T3 (enExample)
GE (2) GEAP201814459A (enExample)
HR (1) HRP20192345T1 (enExample)
HU (1) HUE046894T2 (enExample)
IL (1) IL250692B (enExample)
JO (1) JO3541B1 (enExample)
LT (1) LT3188599T (enExample)
MA (1) MA40607B1 (enExample)
MD (1) MD4710C1 (enExample)
ME (1) ME03597B (enExample)
MX (1) MX361741B (enExample)
MY (1) MY187167A (enExample)
NI (1) NI201700024A (enExample)
PE (1) PE20171109A1 (enExample)
PH (1) PH12017500392B1 (enExample)
PL (1) PL3188599T3 (enExample)
PT (1) PT3188599T (enExample)
RS (1) RS59751B1 (enExample)
SG (1) SG11201701567UA (enExample)
SI (1) SI3188599T1 (enExample)
SV (1) SV2017005400A (enExample)
TN (1) TN2017000040A1 (enExample)
TW (1) TWI639429B (enExample)
UA (1) UA120765C2 (enExample)
UY (1) UY36286A (enExample)
WO (1) WO2016036598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
DK3188599T3 (da) 2014-09-04 2019-11-25 Helsinn Healthcare Sa Medicinske behandlinger baseret på anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY
JP2022514645A (ja) 2018-12-20 2022-02-14 アイミューン セラピューティクス，インコーポレイテッド ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
CN115569120A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
BR112022005457A2 (pt) * 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
JPWO2025004650A1 (enExample) * 2023-06-28 2025-01-02

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2854810A4 (en) 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
DK3188599T3 (da) 2014-09-04 2019-11-25 Helsinn Healthcare Sa Medicinske behandlinger baseret på anamorelin

Also Published As

Publication number Publication date
CN109172575A (zh) 2019-01-11
SI3188599T1 (sl) 2020-02-28
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
JP2018154655A (ja) 2018-10-04
KR20180085047A (ko) 2018-07-25
ECSP17019893A (es) 2017-05-31
PE20171109A1 (es) 2017-08-07
KR20210035923A (ko) 2021-04-01
RS59751B1 (sr) 2020-02-28
AU2015312231A1 (en) 2017-03-23
IL250692B (en) 2019-05-30
US20210093627A1 (en) 2021-04-01
CR20170121A (es) 2017-07-17
US20170296526A1 (en) 2017-10-19
JP7044918B2 (ja) 2022-03-30
JP2021080281A (ja) 2021-05-27
PH12017500392B1 (en) 2018-08-31
UA120765C2 (uk) 2020-02-10
EP3188599B1 (en) 2019-10-02
HUE046894T2 (hu) 2020-04-28
LT3188599T (lt) 2019-12-10
DOP2017000055A (es) 2017-08-15
MD20170025A2 (ro) 2017-07-31
TN2017000040A1 (en) 2018-07-04
CN113577073A (zh) 2021-11-02
WO2016036598A1 (en) 2016-03-10
CL2017000494A1 (es) 2017-09-15
IL250692A0 (en) 2017-04-30
CY1122746T1 (el) 2021-03-12
CN113577074A (zh) 2021-11-02
KR101881264B1 (ko) 2018-07-23
MD4710C1 (ro) 2021-04-30
KR20170047372A (ko) 2017-05-04
US11723902B2 (en) 2023-08-15
EP3188599A1 (en) 2017-07-12
JP2017526695A (ja) 2017-09-14
JP6356907B2 (ja) 2018-07-11
US10278964B2 (en) 2019-05-07
US20240024303A1 (en) 2024-01-25
KR102307275B1 (ko) 2021-09-30
EP3590338A2 (en) 2020-01-08
MX361741B (es) 2018-12-14
EP3188599A4 (en) 2017-10-11
KR102234319B1 (ko) 2021-04-01
CN107375285A (zh) 2017-11-24
AP2017009772A0 (en) 2017-02-28
MA40607B1 (fr) 2019-11-29
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
UY36286A (es) 2016-02-29
PL3188599T3 (pl) 2020-06-01
HRP20192345T1 (hr) 2020-03-20
EP3590338A3 (en) 2020-03-18
TWI639429B (zh) 2018-11-01
ES2761777T3 (es) 2020-05-21
NI201700024A (es) 2017-07-18
PH12017500392A1 (en) 2017-07-17
JO3541B1 (ar) 2020-07-05
US9675600B2 (en) 2017-06-13
SG11201701567UA (en) 2017-03-30
MY187167A (en) 2021-09-07
US20190175574A1 (en) 2019-06-13
NZ729673A (en) 2023-09-29
CO2017003263A2 (es) 2017-07-28
MX2017002825A (es) 2017-09-28
SV2017005400A (es) 2017-04-20
TW201613587A (en) 2016-04-16
CN107205389A (zh) 2017-09-26
AR103118A1 (es) 2017-04-19
GEAP201814459A (en) 2018-09-10
AU2015312231B2 (en) 2017-10-19
PT3188599T (pt) 2020-01-15
US20160067236A1 (en) 2016-03-10
JP6923486B2 (ja) 2021-08-18
MD4710B1 (ro) 2020-09-30
ME03597B (me) 2020-07-20
US10894041B2 (en) 2021-01-19
CA2959158A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
CO2017011564A2 (es) Métodos y kits para tratar la depresión
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MD4710B1 (ro) Tratamente terapeutice pe bază de anamorelin
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
ZA201804696B (en) Therapeutic use of inhibitors of t cell activation or stimulation
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112016020381A8 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
CY1120906T1 (el) Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου
BR112018013189A2 (pt) zaragatoa para amostragem bucal e usos da mesma
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CL2021001554A1 (es) Métodos para el tratamiento de discinesia en parálisis cerebral.
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112019006174A2 (pt) proteina terapêutica
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
UA97357U (en) Method for laser therapy in the treatment of patients with exogenous depressive disorder with suicidal behavior
RU2012124589A (ru) Бандаж и способ его применения при лечении и профилактике послеродовых заболеваний коров

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/40

Ipc: A61K 31/454 (2006.01), A61K 31/00 (2006.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]